Neurotrope and Metuchen Pharmaceuticals announced the companies have merged in an all-stock deal to form Petros Pharmaceuticals, which is focused on men’s health conditions.
As Tocagen heads into a reverse merger with privately held Forte Biosciences, San Diego-based Denovo Biopharma swooped in to snap up that company’s retroviral replicating vector platform (RRV), including an asset that stumbled in a Phase III study that Denovo believes still has some life.
Social distancing measures for COVID-19 are having an impact on the planned merger of Mylan and Pfizer’s off-patent business, Upjohn.
AbbVie and Allergan are closer to completing the $63 billion combination of the two companies after entering into a consent decree agreement with the Federal Trade Commission that commits them to a previously announced divestiture of products ahead of the merger.
As Allergan and AbbVie continue to move forward with their unification, a group of unions and consumer organizations have banded together in opposition to the $63 billion merger citing concerns that the business combination will create a monopoly and harm competition.
Illumina and Pacific Biosciences called off their $1.2 billion merger fourteen months after the deal was announced.
2019 was marked by mergers and acquisitions (M&A), both big and small, as BioSpace reviews some of the top deals.
Tokyo-based Astellas Pharma announced plans to acquire San Francisco-based Audentes Therapeutics for $60 per share in cash, representing a total equity value of about $3 billion.
Bristol-Myers Squibb announced the completed acquisition of Celgene following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced in April 2019, approval by the companies’ stockholders.
Bristol-Myers Squibb Co. and Celgene Corp. won U.S. antitrust approval for their merger on condition that they sell Celgene’s psoriasis drug Otezla.